215 related articles for article (PubMed ID: 17936633)
1. Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives.
Colabufo NA; Berardi F; Cantore M; Perrone MG; Contino M; Inglese C; Niso M; Perrone R; Azzariti A; Simone GM; Porcelli L; Paradiso A
Bioorg Med Chem; 2008 Jan; 16(1):362-73. PubMed ID: 17936633
[TBL] [Abstract][Full Text] [Related]
2. 4-Biphenyl and 2-naphthyl substituted 6,7-dimethoxytetrahydroisoquinoline derivatives as potent P-gp modulators.
Colabufo NA; Berardi F; Cantore M; Perrone MG; Contino M; Inglese C; Niso M; Perrone R; Azzariti A; Simone GM; Paradiso A
Bioorg Med Chem; 2008 Apr; 16(7):3732-43. PubMed ID: 18276145
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy.
Walker J; Martin C; Callaghan R
Eur J Cancer; 2004 Mar; 40(4):594-605. PubMed ID: 14962729
[TBL] [Abstract][Full Text] [Related]
4. 1-Cyclohexyl-4-(4-arylcyclohexyl)piperazines: Mixed σ and human Δ(8)-Δ(7) sterol isomerase ligands with antiproliferative and P-glycoprotein inhibitory activity.
Abate C; Niso M; Contino M; Colabufo NA; Ferorelli S; Perrone R; Berardi F
ChemMedChem; 2011 Jan; 6(1):73-80. PubMed ID: 21069657
[TBL] [Abstract][Full Text] [Related]
5. Substituted tetrahydroisoquinoline compound B3 inhibited P-glycoprotein-mediated multidrug resistance in-vitro and in-vivo.
Fang W; Li Y; Cai Y; Kang K; Yan F; Liu G; Huang W
J Pharm Pharmacol; 2007 Dec; 59(12):1649-55. PubMed ID: 18053326
[TBL] [Abstract][Full Text] [Related]
6. Increased anti-P-glycoprotein activity of baicalein by alkylation on the A ring.
Lee Y; Yeo H; Liu SH; Jiang Z; Savizky RM; Austin DJ; Cheng YC
J Med Chem; 2004 Oct; 47(22):5555-66. PubMed ID: 15481991
[TBL] [Abstract][Full Text] [Related]
7. Interactions of the multidrug resistance modulators tariquidar and elacridar and their analogues with P-glycoprotein.
Pajeva IK; Sterz K; Christlieb M; Steggemann K; Marighetti F; Wiese M
ChemMedChem; 2013 Oct; 8(10):1701-13. PubMed ID: 23943604
[TBL] [Abstract][Full Text] [Related]
8. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells.
Wang TX; Yang XH
Yao Xue Xue Bao; 2008 May; 43(5):461-6. PubMed ID: 18717331
[TBL] [Abstract][Full Text] [Related]
9. Design and syntheses of permethyl ningalin B analogues: potent multidrug resistance (MDR) reversal agents of cancer cells.
Zhang PY; Wong IL; Yan CS; Zhang XY; Jiang T; Chow LM; Wan SB
J Med Chem; 2010 Jul; 53(14):5108-20. PubMed ID: 20560605
[TBL] [Abstract][Full Text] [Related]
10. Reversal of p-glycoprotein-mediated multidrug resistance by macrocyclic bisbibenzyl derivatives in adriamycin-resistant human myelogenous leukemia (K562/A02) cells.
Li X; Sun B; Zhu CJ; Yuan HQ; Shi YQ; Gao J; Li SJ; Lou HX
Toxicol In Vitro; 2009 Feb; 23(1):29-36. PubMed ID: 18938236
[TBL] [Abstract][Full Text] [Related]
11. Phenylsulfonylfuroxans as modulators of multidrug-resistance-associated protein-1 and P-glycoprotein.
Fruttero R; Crosetti M; Chegaev K; Guglielmo S; Gasco A; Berardi F; Niso M; Perrone R; Panaro MA; Colabufo NA
J Med Chem; 2010 Aug; 53(15):5467-75. PubMed ID: 20684594
[TBL] [Abstract][Full Text] [Related]
12. Arylmethyloxyphenyl derivatives: small molecules displaying P-glycoprotein inhibition.
Colabufo NA; Berardi F; Perrone R; Rapposelli S; Digiacomo M; Balsamo A
J Med Chem; 2006 Nov; 49(22):6607-13. PubMed ID: 17064079
[TBL] [Abstract][Full Text] [Related]
13. Novel multidrug resistance reversal agents.
Berger D; Citarella R; Dutia M; Greenberger L; Hallett W; Paul R; Powell D
J Med Chem; 1999 Jun; 42(12):2145-61. PubMed ID: 10377220
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer.
Wong HL; Bendayan R; Rauth AM; Wu XY
J Control Release; 2006 Dec; 116(3):275-84. PubMed ID: 17097178
[TBL] [Abstract][Full Text] [Related]
15. CJY, an isoflavone, reverses P-glycoprotein-mediated multidrug-resistance in doxorubicin-resistant human myelogenous leukaemia (K562/DOX) cells.
Ji BS; He L
J Pharm Pharmacol; 2007 Jul; 59(7):1011-5. PubMed ID: 17637197
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of anticancer effects of newly synthesized dihydropyridine derivatives in comparison to verapamil and doxorubicin on T47D parental and resistant cell lines in vitro.
Bazargan L; Fouladdel S; Shafiee A; Amini M; Ghaffari SM; Azizi E
Cell Biol Toxicol; 2008 Apr; 24(2):165-74. PubMed ID: 17805981
[TBL] [Abstract][Full Text] [Related]
17. Long-circulating PEG-PE micelles co-loaded with paclitaxel and elacridar (GG918) overcome multidrug resistance.
Sarisozen C; Vural I; Levchenko T; Hincal AA; Torchilin VP
Drug Deliv; 2012 Nov; 19(8):363-70. PubMed ID: 23030458
[TBL] [Abstract][Full Text] [Related]
18. The acridonecarboxamide GF120918 potently reverses P-glycoprotein-mediated resistance in human sarcoma MES-Dx5 cells.
Traunecker HC; Stevens MC; Kerr DJ; Ferry DR
Br J Cancer; 1999 Nov; 81(6):942-51. PubMed ID: 10576649
[TBL] [Abstract][Full Text] [Related]
19. Reversal effect of substituted 1,3-dimethyl-1H-quinoxalin-2-ones on multidrug resistance in adriamycin-resistant K562/A02 cells.
Sun LR; Li X; Cheng YN; Yuan HY; Chen MH; Tang W; Ward SG; Qu XJ
Biomed Pharmacother; 2009 Mar; 63(3):202-8. PubMed ID: 18818047
[TBL] [Abstract][Full Text] [Related]
20. Levistolide A overcomes P-glycoprotein-mediated drug resistance in human breast carcinoma cells.
Chen F; Wang T; Wang J; Wang ZQ; Qian M
Acta Pharmacol Sin; 2008 Apr; 29(4):458-64. PubMed ID: 18358092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
